NuVasive Announces FDA Clearance Of PRECICE For Expanded Indications

(RTTNews) - NuVasive, Inc. (NUVA) announced it has received expanded 510(k) clearance from the U.S. FDA for the PRECICE system from NuVasive Specialized Orthopedics with expanded indications that now include open and closed fracture fixation, pseudoarthrosis, malunions, nonunions, and bone transport. Prior to the expanded FDA clearance, the PRECICE system was indicated for limb lengthening of the femur and tibia.

NuVasive said the expanded indications for use allows the company to continue to build a platform for further growth in the limb reconstruction and trauma markets.